Health Technology Assessments are now hosted by Ontario Health. Discover recommendations for which health care tools and services should be publicly funded.
HTA Details
Preimplantation Genetic Testing for Aneuploidy, Monogenic Disorders and Structural Rearrangements
- Publication date
-
2026-June-18
- Status
- In development
- Topic Area
- Genetics
- Recommendation
-
Draft
- Preimplantation Genetic Testing for Aneuploidy (PGT-A)
Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, recommends against publicly funding PGT-A for people undergoing in vitro fertilization. - Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)
Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, concludes there is currently insufficient evidence to make a recommendation for or against publicly funding PGT-M. - Preimplantation Genetic Testing for Structural Rearrangements (PGT-SR)
Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, concludes there is currently insufficient evidence to make a recommendation for or against publicly funding PGT-SR for people undergoing in vitro fertilization.
- Preimplantation Genetic Testing for Aneuploidy (PGT-A)
-
Thank you for your comments
The public feedback period for this topic has ended. All comments will be considered before a final recommendation is made and posted here.
Read the latest recommendation report.
Preimplantation genetic testing (PGT) refers to a group of genetic tests that analyze the DNA of an embryo for chromosomal or genetic anomalies prior to transfer to the uterus during in vitro fertilization (IVF). PGT-A can be offered to any couple or person undergoing IVF to screen their embryos for an atypical number of chromosomes. In contrast, PGT-M and PGT-SR are intended for individuals with known genetic risk; either people who are carriers of or affected by a monogenic disorder, and thus, are at risk of passing it on to offspring (PGT-M), or people who are carriers of or have a chromosomal structural rearrangement that may lead to chromosomally unbalanced gametes (sperm or egg) associated with infertility or recurrent pregnancy loss (PGT-SR). Although indications and populations for PGT-A, PGT-M, and PGT-SR differ, similar biopsy and genetic testing methods are used for the 3 types of testing, and the tests may be performed concurrently.
Ontario Health conducted health technology assessments (HTAs) on PGT, including evaluations of the clinical and economic impact of PGT-A, the clinical impact of PGT-M, and the clinical impact of PGT-SR; a rapid review of the obstetrical and neonatal harms of PGT; and direct patient engagement to explore their preferences and values. In addition, Ontario Health partnered with Canada’s Drug Agency to assess the qualitative literature on patient and provider preferences for PGT and analyze ethical considerations related to PGT. The Ontario Health Technology Advisory Committee and its subcommittee the Ontario Genetics Advisory Committee examined and deliberated on the totality of the evidence encompassed by these health technology assessments in arriving at their recommendations.
Contact
For questions about this draft recommendation, please contact HealthInnovationPathway@ontariohealth.ca.
Supporting Documents
Last Updated: June 29, 2026
